Taliaz

Company Overview

Snapshot

Founded in August 2012 by Dekel Taliaz and Oren Taliaz, Taliaz operates with 11–50 employees. The company has raised $3.2M across two funding rounds. In October 2022, Taliaz partnered with Cerba to leverage artificial intelligence and genetics expertise to improve patient care management in depression.

Business overview

Taliaz develops Predictix, an AI-based platform designed to assist doctors in delivering personalized medicine. The core technology utilizes proprietary IP to generate doctor-centric therapy prediction reports for individual patients, serving as a decision-support tool for general practitioners and specialists. The company's flagship application, the Predictix Anti-Depressant AI system, analyzes genomic, clinical, and demographic data to optimize antidepressant treatment strategies. Taliaz operates in the Health Tech & Life Sciences sector, focusing on digital healthcare and medical decision support, with its application commercially available in the EU and Israel.

Strategic signal

In October 2022, Taliaz announced a partnership with Cerba to combine artificial intelligence with genetics expertise to enhance patient care management for depression. This collaboration signals a strategic move towards integrating advanced AI diagnostics with established healthcare providers, aiming to improve treatment outcomes and validate Taliaz's technology within the broader medical community.

Company Intelligence Q&A

What is Taliaz's core product?

Taliaz's core product is Predictix, an AI-based platform that generates personalized therapy prediction reports for individual patients, particularly focusing on optimizing antidepressant treatment strategies.

When was Taliaz founded and by whom?

Taliaz was founded in August 2012 by Dekel Taliaz and Oren Taliaz.

What is the primary focus of Taliaz's AI system?

The Predictix Anti-Depressant AI system analyzes genomic, clinical, and demographic data to provide statistical analysis on the efficacy and side effects of antidepressants, helping doctors optimize treatment choices for depression.

What significant partnership did Taliaz announce in October 2022?

In October 2022, Taliaz announced a partnership with Cerba to leverage artificial intelligence and genetics expertise to improve patient care management in depression.

In which markets is Taliaz's application commercially available?

Taliaz's Predictix application is currently available for commercial use in the EU and Israel.